Background Relief of cancer pain from opioids is rarely all or nothing; most patients experience some degree of analgesia alongside opioid toxicities. When the balance of analgesia versus toxicity tips away from analgesia, the term ‘opioid poorly-responsive pain’ is invoked. While opioid poorly-responsive pain is not a discreet syndrome, it is a commonly encountered clinical scenario. This Fast Fact reviews key points in its assessment and management.
Differential Diagnosis of Opioid Poorly-Responsive Pain
- Cancer-related pain
- Cancer progression (new fracture at site of known bone metastases).
- Causes of pain (eg. neuropathic pain, skin ulceration, rectal tenesmus, muscle pain) that are known to be less responsive to systemic opioids or opioid monotherapy.
- Psychological/spiritual pain related to the cancer experience (existential pain of impending death).
- Opioid pharmacology/technical problems
- Opioid tolerance (rapid dose escalation with no analgesic effect).
- Dose-limiting opioid toxicity (sedation, delirium, hyperalgesia, nausea – see Fast Facts #25, 142).
- Poor oral absorption (for PO meds) or skin absorption (e.g. transdermal patch adhesive failure).
- Pump, needle, or catheter problems (IV, subcutaneous, or spinal opioids).
- Non-cancer pain
- Worsening of a known non-cancer pain syndrome (diabetic neuropathy).
- New non-cancer pain syndrome (dental abscess).
- Other psychological problems
- Depression, anxiety, somatization, hypochondria, factitious disorders.
- Dementia and delirium both can effect a patient’s report of and experience of pain.
- Opioid substance use disorders or opioid diversion.
- Initial Steps
- Complete a thorough pain assessment including questions exploring psychological and spiritual concerns. If substance abuse or diversion is suspected, complete a substance abuse history (see Fast Facts #68, 69).
- Complete a physical examination and order diagnostic studies as indicated.
- Escalate a single opioid until acceptable analgesia or unacceptable toxicity develop, or it is clear that additional analgesic benefit is not being derived from dose escalation. If this fails, consider:
- Rotating to a different opioid (e.g. morphine to methadone).
- Changing the route of administration (e.g. oral to subcutaneous).
- Treat opioid toxicities aggressively.
- Use (start or up-titrate) adjuvant analgesics, especially for neuropathic pain syndromes.
- Integrate non-pharmacological treatments such as behavioral therapies, physical modalities like heat and cold, and music and other relaxation-based therapies – see Fast Fact #211.
- Additional steps – Pain refractory to the initial steps requires multi-disciplinary input and care coordination.
- Hospice/Palliative Medicine consultation to optimize pain assessment, drug management, and assessment of overall care goals.
- Mental health consultation for help in diagnosis and management of suspected psychological factors contributing to pain.
- Chaplain/Clergy assistance for suspected spiritual factors contributing to pain.
- Interventional Pain and/or Radiation Oncology consultation.
- Rehabilitation consultations (Physiatry, Physical and Occupational Therapy) to maximize physical analgesic modalities.
- Pharmacist assistance with drug/route information.
- Mercadante F, Portenoy RK. Opiate Poorly Responsive Cancer Pain Parts 1-3. J Pain Symptom Management. 2001; 21(2):144-150, 21(3):255-264, 24(4):338-354.
- Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20(19):4040-9.
- Fallon M. When morphine does not work. Support Care Cancer. 2008; 16(7):771-5.
- Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews. 2004, Issue 3. Art. No.: CD004847. DOI: 10.1002/14651858.CD004847.
- Hanks GW. Opioid-responsive and opioid-non-responsive pain in cancer. Br Med Bull. 1991; 47(3):718-31.
- Hanks G, Forbes K. Opioid responsiveness. Acta Anaesthesiologica Scand.1997; 41:154-158.
Author Affiliations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (TS, RA), and Medical College of Wisconsin, Milwaukee, Wisconsin (DEW).
Version History: Originally published May 2009; copy-edited August 2015.
Fast Facts and Concepts are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual Fast Fact are solely responsible for that Fast Fact’s content. The full set of Fast Facts are available at Palliative Care Network of Wisconsin with contact information, and how to reference Fast Facts.
Copyright: All Fast Facts and Concepts are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (http://creativecommons.org/licenses/by-nc/4.0/). Fast Facts can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!
Disclaimer: Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.